102 results about "Respiratory complex II" patented technology

An approach to noninvasively, remotely and accurately detect core body temperature in a warm-blooded subject, human or animal, via thermal imaging. Preferred features such as the use of in-frame temperature references, specific anatomical target regions and a physiological heat transfer model help the present invention to overcome pitfalls inherent with existing thermal imaging techniques applied to physiological screening applications. This invention provides the ability to noninvasively, remotely and rapidly screen for diseases or conditions that are characterized by changes in core body temperature. One human application of this invention is the remote screening for severe acute respiratory syndrome (SARS), since fever is a common, early symptom. Other diseases and conditions that affect the core body temperature of humans or animals may also be noninvasively and remotely detected with this invention.

The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.

The purpose of the invention is to disclose a porcine circovirus, porcine parvovirus and porcine reproductive and respiratory syndrome virus triplex virus-like particle vaccine and its preparation method. The triple virus-like particle vaccine (Triple VLP vaccine) of the invention contains VLP which is composed of PCV-2 major structural protein CAP protein, PPV VP2 protein epitope and PRRSV Gp5 protein epitope. It is proved by experiment that the vaccine can stimulate good double cellular and humoral immune response. It is shown by pharmacodynamic test that after immunization of different animal groups, the vaccine of injection, nose drops and water forms prepared by VLP antigen formed by the method with or without adjuvants can safely and effectively prevent the infection of PCV-2, PPV and PRRSV. The invention provides an ideal vaccine for the security of sows, piglets and fattening pigs to effectively prevent mixed infection of PCV-2, PPV and PRRSV.

The present invention provides isolated European-like porcine reproductive and respiratory syndrome viruses, polynucleotides, and polypeptides. The present invention also provides methods for making antibodies to the viruses and polypeptides, methods for detecting porcine reproductive and respiratory syndrome viruses, immunogenic compositions, and methods for treating a porcine subject at risk of infection by, or displaying symptoms of, a porcine reproductive and respiratory syndrome virus infection.

An application of sophocarpine in preparing the medicine for treating the medicines caused by coronavirus and the process for preparing the medicine from sophocarpine to treat SARS are disclosed.

The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention.

The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.

The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequences. Furthermore, the invention relates to vaccine preparations comprising the SCoV-like virus, including recombinant and chimeric forms of said virus.

The present disclosure provides vaccine compositions comprising a PRRSV vaccine and a second porcine vaccine, which are substantially free from immuno-inhibition against each other. The second porcine virus vaccine can be CSFV and/or PRV. The preparation methods for the vaccines and the formulations are also provided. The vaccine compositions provided herein confer protective immunity to pigs against porcine reproductive and respiratory syndrome, classical swine fever, and/or pseudorabies.

The invention discloses a prescription composition of a pig antiviral semen diluent. Based on every 1000ml of double distilled water, the pig antiviral semen diluent contains 15.50g of glucose, 11.65g of trisodium citrate, 2.35g of EDTA sodium salt, 1.75g of sodium bicarbonate, 1.00g of polyvinyl alcohol, 5.50g of tricarboxymethyl amino methane, 4.10g of citric acid, 0.07g of cysteine, 1.00g of vitamin C, 0.10g of enrofloxacin and 50ml of an antiviral agent. According to the embodiment of the invention, the diluent of the prescription composition of the pig antiviral semen diluent has obvious killing, inhibition and obstructing effects on pig reproduction and respiration syndrome virus (PRRSV) and is capable of obviously improving the survival rate and preservation time of semen during in vitro preservation and the litter size of a mated sow.

The invention discloses a triple fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection reagent for African swine fever viruses, swine fever viruses and respiratory syndrome viruses and a preparation method and application thereof. Three sets of specific primers and Taqman probes as well as positive controls specific to African swine fever virus CP530R genes, swine fever virus 5 minute-UTR genes and swine respiratory syndrome virus NSP2 genes respectively are designed and synthesized, and a rapid, easy and convenient triple fluorescent RT-PCR detection system with high specificity and high sensitivity is established by using the three sets of primers and probes, so that nucleic acids of the African swine fever viruses, the swine fever viruses and the respiratory syndrome viruses can be detected synchronously from a detected sample within 3-4 hours in a rapid, accurate, specific, safe, easy and convenient way. The detection reagent can be applied to synchronous detection of the nucleic acids of trace African swine fever viruses, swine fever viruses and respiratory syndrome viruses in hogs and relevant samples thereof.

The invention provides a synthetic peptide vaccine for treating porcine reproductive and respiratory syndrome and a preparation method thereof, in particular relates to polypeptide of the synthetic peptide vaccine for treating the porcine reproductive and respiratory syndrome and a vaccine which contains the polypeptide and a method for preparing the polypeptide and the vaccine. The amino acid sequence of the polypeptide is an amino acid sequence shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 or SEQ ID No.4. The vaccine prepared from the polypeptide can effectively cope with the antigenic variation of a porcine reproductive and respiratory syndrome virus, ensures biological safety, is easy for large-scale synthesis and has good application prospect.

The invention provides a preparation method of an inactivated and concentrated vaccine 'SD1 strain' for a Porcine reproductive and respiratory syndrome, which is prepared with a water phase and an oil phased according to the following weight percentage content: the water phase is prepared by fully mixing 96 shares of 'SD1 strain' virus culture solution, which is American Porcine reproductive and respiratory syndrome that is inactivated for 20 hours and concentrated 2 times, with 4 shares of Tween minus 80, which occupies 33 percent of the vaccine; the oil phase is prepared by mixing 94 shares of No. 10 white oil with 6 shares of Span minus 80 and then adding a 2 percent aluminum stearate according to the total amount to stir to be transparent, and sterilizing with a high pressure at a temperature of 116 DEG C, which occupies 67 percent of the total amount of the vaccine. The vaccine, with a preservation period of 12 months, is safe and reliable to the Porcine reproductive and respiratory syndrome easily infected animals, and is suitable for pigs of different species and various day old, the immunity protection rate of which reaches 80 percent above, the immunity period of validity of which continues more than 6 months. The safety and immunity efficacy of the vaccine reaches an advanced level among the similar products in the world.

The invention discloses a porcine reproductive and respiratory syndrome virus attenuated vaccine strain, and the microorganism collection number is CGMCC NO.1883. The attenuated vaccine strain of the invention has stable genetic variation and good safety, which is safe and non-pathogenic for pregnant sows, piglets and the pigs at various ages. The immunized piglets after using the attenuated vaccine strain of the invention for immunization can resist the attack of the strong virus of the porcine reproductive and respiratory syndrome virus.

Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).

The invention discloses an RT-PCR (Reverse Transcription-Polymerase Chain Reaction) method for detecting porcine reproductive and respiratory syndrome virus (PRRSV) classical strains, high-pathogenicity variant strains and NADC-30 strains. A pair of primers are designed by applying Primer5.0 software through referring to a PRRSV Nsp2 gene sequence published in GenBank. The pair of primers can be used for detecting three subtypes with different amino acid quantities of a PRRSV through an RT-PCR method. The RT-PCR method disclosed by the invention has high sensitivity and good specificity, and can be used for successfully detecting the three subtypes of the PRRSV, such as the classical strains, the variant strains ad the NADC-30 strains, and can be used for detecting clinical samples with the suspected PRRSV, so that the RT-PCR method is used for diagnosing the PRRSV and carrying out epidemiological monitoring.

The invention relates to a reagent kit used for detecting porcine reproductive and respiratory syndrome virus and a detection method thereof. The reagent kit comprises a RNA enzyme inhibitor, AMV revertase, Taq enzyme, RNA-free enzyme solution, One Step RNA PCR mixed solution and a mixture of primers with negative control and sequence selected from SEQ ID NO: 1 to SEQ ID NO:6. The detection method comprises the step of using the reagent kit to carry out RT-PCR amplification. The method can detect the porcine reproductive and respiratory syndrome virus fast, sensitively and exactly with low cost.

The invention discloses a double fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection reagent for African swine fever viruses and porcine reproductive and respiratory syndrome viruses and a preparation method and application thereof. Two sets of specific primers and Taqman probes as well as positive controls specific to African swine fever virus CP530R genes and porcine reproductive and respiratory syndrome virus NSP2 genes respectively are designed and synthesized, and a rapid, easy and convenient double real-time fluorescent quantitative RT-PCR detection system with high specificity and high sensitivity is established by using the two sets of primers and probes, so that nucleic acids of the African swine fever viruses and the porcine reproductive and respiratory syndrome viruses can be detected synchronously from a detected sample within 3-4 hours in a rapid, accurate, specific, safe, easy and convenient way. The detection reagent can be applied to synchronous detection of the nucleic acids of trace African swine fever viruses and porcine reproductive and respiratory syndrome viruses in hogs and relevant samples thereof.